Published March 11, 2020 | Version v1
Dataset Restricted

Dataset related to article "Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association (AIRO)"

  • 1. Humanitas Clinical and Research Center – IRCCS -, via Manzoni 56, 20089 Rozzano (Mi) - Italy
  • 2. Advanced Radiotherapy Center, UPMC San Pietro FBF, Roma, Italy.
  • 3. Radiotherapy Unit, Istituto Neurologico Fondazione "Carlo Besta", Milan, Italy.
  • 4. Radiation Therapy Unit, Department of Oncology and Advanced Technology, Azienda Ospedaliera Arcispedale S Maria Nuova, Reggio Emilia, Italy.
  • 5. Proton Therapy Center, Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy.
  • 6. Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • 7. Radiotherapy Unit, Department of Translation Medicine, University of Piemonte Orientale, Novara, Italy.
  • 8. Radiotherapy Oncology Centre, "S. Maria" Hospital, Terni, Italy.
  • 9. UOC Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori -Fondazione "Giovanni Pascale", Naples, Italy.
  • 10. Radiation Therapy, Ospedale Ca' Foncello di Treviso, Treviso, Italy.
  • 11. Radiotherapy Unit, Istituto Neurologico Fondazione "Carlo Besta", Milan, Italy
  • 12. Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
  • 13. Radiation Oncology, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  • 14. Radiation Oncology, Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy.
  • 15. Department of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
  • 16. Humanitas Clinical and Research Center – IRCCS -, via Manzoni 56, 20089 Rozzano (Mi) - Italy AND Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy

Description

Abstract

INTRODUCTION:

The prognosis of glioma is dismal, and almost all patients relapsed. At recurrence time, several treatment options are considered, but to date there is no a standard of care. The Neurooncology Study Group of the Italian Association of Radiation Oncology (AIRO) collected clinical data regarding a large series of recurrent glioma patients who underwent re-irradiation (re-RT) in Italy.

METHODS:

Data regarding 300 recurrent glioma patients treated from May 2002 to November 2017, were analyzed. All patients underwent re-RT. Surgical resection, followed by re-RT with concomitant and adjuvant chemotherapy was performed. Clinical outcome was evaluated by neurological examination and brain MRI performed, 1 month after radiation therapy and then every 3 months.

RESULTS:

Re-irradiation was performed at a median interval time (IT) of 16 months from the first RT. Surgical resection before re-RT was performed in 19% of patients, concomitant temozolomide (TMZ) in 16.3%, and maintenance chemotherapy in 29%. Total doses ranged from 9 Gy to 52.5 Gy, with a median biological effective dose of 43 Gy. The median, 1, 2 year OS were 9.7 months, 41% and 17.7%. Low grade glioma histology (p  ≪ 0.01), IT > 12 months (p = 0.001), KPS > 70 (p = 0.004), younger age (p = 0.001), high total doses delivered (p = 0.04), and combined treatment performed (p = 0.0008) were recorded as conditioning survival.

CONCLUSION:

our data underline re-RT as a safe and feasible treatment with limited rate of toxicity, and a combined ones as a better option for selected patients. The identification of a BED threshold able to obtain a greater benefit on OS, can help in designing future prospective studies.

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

This set of raw data is accessible under request because they include sensitive information.

Please write your request at biblioteca@humanitas.it

You are currently not logged in. Do you have an account? Log in here

Additional details

Related works

Is supplement to
0515706 (PMID)
10.1007/s11060-018-03059-x (DOI)